Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

127.85
-0.0500-0.04%
Post-market: 127.76-0.0900-0.07%19:58 EDT
Volume:3.07M
Turnover:392.43M
Market Cap:8.27B
PE:-52.11
High:128.07
Open:128.07
Low:127.77
Close:127.90
Loading ...

Blueprint Shareholders Will Receive One Non-Tradeable Contingent Value Right (CVR) Which Will Entitle Holder to Receive Two Potential Milestone Payments of $2 and $4 per CVR for Achievement, Respectively, of Future Development and Regulatory Milestones for Blu-808

THOMSON REUTERS
·
02 Jun

Sanofi - Total Equity Value of Blueprint Transaction, Including Potential CVR Payments, Represents Approximately $9.5 Bln on a Fully Diluted Basis

THOMSON REUTERS
·
02 Jun

Jeffrey W. Albers, Director, Reports Disposal of Common Shares of Blueprint Medicines Corporation

Reuters
·
30 May

Christina Rossi, Chief Operating Officer, Reports Disposal of Common Shares of Blueprint Medicines Corporation

Reuters
·
22 May

Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates

Simply Wall St.
·
04 May

Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
03 May

Stock Track | Blueprint Medicines Soars 5.01% Despite Q1 Earnings Miss as Ayvakit Sales Surge and 2025 Guidance Raised

Stock Track
·
03 May

Stock Track | Blueprint Medicines Soars 5% Intraday Following Raised 2025 Guidance and Strong Ayvakit Sales

Stock Track
·
03 May

Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

Zacks
·
03 May

Blueprint Medicines Price Target Maintained With a $135.00/Share by HC Wainwright & Co.

Dow Jones
·
02 May

Barclays Remains a Hold on Blueprint Medicines (BPMC)

TIPRANKS
·
02 May

Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...

GuruFocus.com
·
02 May

Q1 2025 Blueprint Medicines Corp Earnings Call

Thomson Reuters StreetEvents
·
02 May

Blueprint Medicines Corp. Reports Strong Earnings Growth

TIPRANKS
·
02 May

Positive Outlook for Blueprint Medicines Driven by Strong Ayvakit Performance and Pipeline Progress

TIPRANKS
·
02 May

Stock Track | Blueprint Medicines Soars 5.06% as Q1 Results Beat Expectations and Company Raises Full-Year Guidance

Stock Track
·
01 May

Blueprint Medicines' Q1 Earnings Decline, Revenue Increases

MT Newswires Live
·
01 May

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Blueprint Medicines (BPMC) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
01 May

Blueprint Medicines Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
01 May

Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

Zacks
·
01 May